SCHEMBL25938752

SCHEMBL25938752

Cc1ccc(O[C@H]2CC[C@H](NC(=O)OC(C)(C)C)C2)c(Br)n1

nearest known ligand 0.43

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
PIK3CD O00329 2/20 0.43
KDM1A O60341 1/20 0.41
MAOB P27338 1/20 0.41
BTK Q06187 4/20 0.40
CKS1B P61024 1/20 0.38
SKP1 P63208 1/20 0.38
SKP2 Q13309 1/20 0.38
JAK1 P23458 3/20 0.38
KMT2A Q03164 1/20 0.38
L3MBTL1 Q9Y468 1/20 0.38
DRD2 P14416 2/20 0.37
CACNB4 O00305 1/20 0.37
CACNA1A O00555 1/20 0.37
CACNA1G O43497 1/20 0.37
CACNG3 O60359 1/20 0.37
CACNA1F O60840 1/20 0.37
CACNA1H O95180 1/20 0.37
CACNB3 P54284 1/20 0.37
CACNA2D1 P54289 1/20 0.37
CACNG7 P62955 1/20 0.37

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL25938848 0.88 PIK3CD (0.41) PIK3CDKDM1AMAOBBTKCKS1B
SCHEMBL30101572 0.88 PIK3CD (0.41) PIK3CDKDM1AMAOBBTKCKS1B
SCHEMBL25938913 0.86 BTK (0.40) PIK3CDKDM1AMAOBBTKCKS1B
SCHEMBL25938889 0.86 PIK3CD (0.41) PIK3CDKDM1AMAOBBTKCKS1B
SCHEMBL25938773 0.86 PIK3CD (0.40) PIK3CDKDM1AMAOBBTKCKS1B
SCHEMBL30101617 0.86 PIK3CD (0.41) PIK3CDKDM1AMAOBBTKCKS1B
SCHEMBL30101528 0.86 BTK (0.40) PIK3CDKDM1AMAOBBTKCKS1B
SCHEMBL30101514 0.86 PIK3CD (0.40) PIK3CDKDM1AMAOBBTKJAK1
SCHEMBL30101627 0.86 PIK3CD (0.40) PIK3CDKDM1AMAOBBTKCKS1B
SCHEMBL25938914 0.86 PIK3CD (0.40) PIK3CDKDM1AMAOBBTKJAK1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20230310423-A1 CHECKPOINT KINASE 1 (CHK1) INHIBITORS AND USES THEREOF BOUNDLESS BIO, INC. 2023-10-05 US disclosed
US-11707462-B2 Checkpoint kinase 1 (CHK1) inhibitors and uses thereof BOUNDLESS BIO, INC. (US) 2023-07-25 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20230310423-A1 CHECKPOINT KINASE 1 (CHK1) INHIBITORS AND USES THEREOF CHEK1, CHEK2, RAD1 PIK3CD 836/4885KDM1A 1547/4885MAOB 4683/4885
US-11707462-B2 Checkpoint kinase 1 (CHK1) inhibitors and uses thereof CHEK1, CHEK2, RAD1 PIK3CD 836/4885KDM1A 1547/4885MAOB 4683/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.